The differential sensitivities of inbred strains of mice to lymphoma development after infection with oncogenic retroviruses have provided opportunities to identify host and viral genes critical to the process. BALB/c mice are susceptible to tumor induction by Abelson murine leukemia virus (A-MuLV), whereas C57BL/6 (B6) mice are resistant; at least two genes control this phenotype (28) . Likewise, BALB/c mice are susceptible and B6 mice are relatively resistant to lymphoma induction by Moloney murine leukemia virus (M-MuLV) (11) . Because the two viruses show similar host range patterns among inbred mice and because M-MuLV was used as the helper virus for A-MuLV tumor studies, we sought to determine whether the genes governing sensitivity and resistance to each virus were the same.
A-MuLV was derived by recombination between MMuLV and the cellular proto-oncogene c-abl, an event which resulted in the deletion of essential viral genes from M-MuLV and generation of the transforming gene v-abl, comprised of both M-MuLV gag sequences and c-abl sequences (12, 27, 42) . Thus M-MuLV and A-MuLV contain the same viral long terminal repeat (LTR) controlling elements. Molecular recombination experiments between MMuLV and the erythroleukemia-inducing Friend MuLV indicated that the M-MuLV LTR is the major determinant of lymphotropism (4) . The mechanics of tumor induction by A-MuLV or M-MuLV are quite different. M-MuLV does not encode a viral oncogene and does not transform cells in culture. Tumor induction by M-MuLV requires a long latent period, and activation of transcription from cellular loci such as pim-1 and c-myc has been implicated in disease induction (7, 8, 36) . In contrast, lymphoma induction and in vitro transformation of cells by A-MuLV is rapid and clearly depends upon the structural and functional integrity of the v-abl oncogene (25, 39, 45) . Additional factors are involved in A-MuLV lymphomagenesis because disease induction, though not focus induction on established lines, requires leukemogenic helper viruses (31, 34) . Furthermore, tumors that lack A-MuLV proviruses have been recovered from A-MuLV-infected mice (15, 21) .
The tissue tropism of A-MuLV also differs from that of * Corresponding author.
M-MuLV. A-MuLV transforms in vitro pre-B and B cells but not T cells (30, 37) . Tumors of the B-cell lineage have been recovered from A-MuLV-infected mice as have tumors of other hematopoietic cell types (24, 26, 38) . A recent study indicated that after intrathymic infection of mice, A-MuLV rapidly induced tumors of the T-cell lineage (5, 6) . The predominant tumor cell type recovered from M-MuLVinfected mice is usually described as a T cell (22) , although one study noted that this phenotype appeared to depend on the mouse strain (3).
MATERIALS AND METHODS
Viruses and cell lines. Bioiogically cloned M-MuLV was prepared by harvest of supernatant fluids from NIH 3T3 cells productively infected with M-MuLV cl 1 (9) . A-MuLV (P160) was prepared by superinfecting nonproducer N54 cells with M-MuLV cl 1 (32) . A-MuLV (P90) was prepared by infecting the N25 nonproducer cell with M-MuLV cl 1 (30) . N54 and N25 nonproducer cells were generously provided by N. Rosenberg, Tufts University, Boston, Mass. The titer of replication-competent MuLV was determined by the UV-XC plaque assay (33) , and the titer of transforming A-MuLV was determined by focus formation on NIH 3T3 cells (35 ; 600 Ci/mmol) in methionine-free RPMI 1640 medium supplemented with 10% dialyzed fetal bovine serum. All labeling times were 3 h at 37°C. After labeling, the cells were washed with RPMI 1640 medium and lysed in a volume equal to the labeling volume with phosphate lysis buffer: 10 mM phosphate (pH 7.4), 0.1% sodium dodecyl sulfate, 0.5% deoxycholate, 1% Triton X-100, 0.1 ,ug of bovine serum albumin per ml, and 1% Trasylol (44) . The lysates were centrifuged at 15,000 x g for 15 min and precleared by the addition of normal goat serum and S. aureus Cowen 1 strain prepared by the method of Kessler (16) . Immunoprecipitation was performed as described previously (15) except that phosphate lysis buffer was used as a wash buffer instead of RIPA buffer.
Briefly, 50 RI of cell lysate was mixed with antibody, incubated at 4°C for 1 h, followed by the addition of 100 ,u1 of a 10% solution of S. aureus Cowen 1 strain, and incubated for an additional hour. The antigen-antibody complexes were washed four times with phosphate lysis buffer and eluted from the bacteria by the addition of 50 ,u1 of sample buffer and heating at 100°C for 5 min. The eluted proteins were separated on sodium dodecyl sulfate-polyacrylamide gels as described by Laemmli (18) . Proteins labeled with 35S were visualized fluorographically by treatment of the sodium dodecyl sulfate-polyacrylamide gels with En3Hance (New England Nuclear Corp.). " Mice bred in our colony were infected by intraperitoneal injection at 0 to 2 days of age or by intravenous injection at 20 to 30 days of age with 0.1 ml of medium containing 5 x 104 to 1 x 105 PFU of M-MuLV. Mice were scored biweekly for lymphoma development. b Incidence is the number of mice that developed lymphoma within 180 day/ number of mice infected. All experiments were terminated at 180 days, except for experiments with mice infected at 20 to 30 days of age. Statistical comparison by the Fisher two-tailed test indicated that BALB/c mice differed significantly from B6 mice and from CXB K mice in lymphoma incidence (P < 0.001) and did not differ significantly from Es G. J, or CBF1 (P > 0.1). The difference in lymphoma incidence of BALB/c mice compared with H mice is probably significant (P = 0.03). The lymphoma incidence of B6 and CXB K mice did not differ significantly (P > 0.1).
RESULTS

Susceptibility
' Statistical analysis of the latent periods by the method of Gehan (10) indicated that BALB/c mice differed significantly from 86, CBF1, E, H. I, J, and K mice (P < 0.001) but did not differ significantly from G mice (P > 0.1). Statistical comparison of the latent period of B6 and K mice indicated that they did not differ significantly (P > 0.1). "These numbers indicate the time at which the experiment was terminated.
105 PFU of M-MuLV. Mice were observed twice weekly for 6 months postinfection for signs of dypsnea, lymphadenopathy, or splenomegaly. More than 90% of BALB/c mice developed lymphomas, with a median latent period of 92 days (Table 1 ). In contrast, only 31% of B6 mice developed tumors, with a median latent period of 120 days (Table 1) . When infected intravenously with M-MuLV as young adults, both BALB/c and B6 mice were refractory to tumor induction in the time period examined. We also tested the susceptibility of (BALB/c x B6)F1 mice to M-MuLV tumor induction and found that 79% developed tumors, with a median latent period of 110 days (Fig. 1, Table 1 ).
For an unambiguous comparison of A-MuLV and MMuLV susceptibility, we repeated some of our earlier studies (28) with biologically cloned A-MuLV pseudotyped with the same pool of M-MuLV used in the present study. Mice at 2 to 3 months of age were injected intravenously with 2.5 x 103 to 5 x 103 FFU of A-MuLV and observed for the development of tumors. As previously reported, the great majority of young adult BALB/c mice developed nonthymic lymphomas approximately 30 days postinfection with AMuLV. In contrast, only 5% of B6 mice infected at the same age developed lymphomas (Fig. 2) . From Fig. 3 ).
The remaining four strains E, H, I, and J showed highly c susceptible patterns of tumor incidence but longer latent periods than BALB/c mice. (Table 2 ). This conclusion must be qualified because M-MuLV susceptibility patterns were determined in newborn mice and A-MuLV susceptibility patterns were infected with A-MuLV, although high incidences of disease were found in both strains (28) .
Thymoma induction by A-MuLV. Because many of the M-MuLV tumors developed in the thymus and were of T-cell origin (see below), we sought to determine whether similar cell types could be transformed in vivo by A-MuLV, as reported by Cook (5) . We injected intrathymically 10 (32) . No tumors were observed in B6 mice infected intrathymically with A-MuLV (P90).
To determine whether the v-abl product was expressed in thymic lymphomas, three B6 A-MuLV thymic lymphoma lines that had been adapted to tissue culture were examined for P160 expression. Cell lines were metabolically labeled with [35S]methionine, and proteins were immunoprecipitated with control or anti-gag p15 serum. p160 expression was readily detected in each of the tumor cell lines (Fig. 4) .
Cellular phenotypes of A-MuLV and M-MuLV tumors. The cellular phenotypes of several A-MuLV and M-MuLV tumor cell lines were examined with four lineage-restricted cell surface markers. The markers used were the B-cell restricted B220 glycoprotein and the T-cell markers Thy-1, (10) " Time at which the experiment was terminated.
Ly-1, and Lyt-2. Primary tumors were cultured in vitro for 3 to 6 weeks before testing to avoid complications introduced in phenotyping mixtures of primary tumor and normal cells. Each cell line classified as positive in Table 4 showed >70% positive cells, whereas each negative line showed background levels of antibody binding. The three lymphomas established from tumors induced by A-MuLV intravenous infection of BALB/c, CBF1, or B6 mice expressed high quantities of B220 and no T-cell markers, a phenotype consistent with that of a pre-B or B cell. Of the A-MuLV thymoma lines analyzed, six did not express detectable quantities of any of these markers and cannot be classified, or must be classified as null cells. One line expressed only Thy-1 and is therefore likely to be a T cell. One line expressed B220 and Ly-1, a phenotype recently associated with a subset of normal B cells (19) .
With one exception, M-MuLV tumors all appeared to be of T-cell origin in that the majority of cells in the tumor population reacted with two or more of the T-cell restricted markers Thy-1, Ly-1, or Lyt-2. Although neither Thy-1 nor Ly-1 is exclusively found on T cells, dual expression of both has not been reported for any normal non-T cell. Among the limited set of M-MuLV tumors examined here, the three populations of thymic lymphocytes, i.e., Thy-1+, Ly-1+, and Lyt-2+; Thy-1+, Ly-1 1, and Lyt-2+; and Thy-1+, Ly-1+, Lyt-2-cells, are all represented. One additional cell of Thy-l+ Ly-1-Lyt-2-phenotype also was encountered.
DISCUSSION
The results presented here demonstrate that BALB/c mice are susceptible to lymphoma induction by either A-MuLV or M-MuLV and that B6 mice are relatively resistant to tumor induction by each virus. Since nonparental patterns of susceptibility segregated in recombinant inbred strains made between BALB/c and B6, susceptibility to each virus is controlled by multiple genes of the mouse ( Fig. 3; 28) . The genes that control susceptibility to either virus segregate independently in CXB strains. For example, G mice are highly susceptible to M-MuLV disease yet resistant to A-MuLV disease. Conversely, H mice are as sensitive as BALB/c mice to A-MuLV disease yet develop fewer MMuLV tumors with longer latent periods than do M-MuLVinfected BALB/c mice. These results make it unlikely that susceptibility to A-MuLV lymphoma induction is determined solely by host responses to the helper virus, because the pattern of A-MuLV susceptibility would then be expected to follow that of the helper virus. It also seems unlikely that susceptibility to A-MuLV is a function of the A-MuLV LTR since the LTRs of A-MuLV and M-MuLV are very similar (27) . This conclusion is less firm, however, because several point mutations distinguish the M-MuLV and A-MuLV LTRs, and these changes could play important roles in tissue tropism and thereby affect host strain susceptibility.
The latent periods for tumor development by either virus are very different, and the apparent cellular targets for tumor induction by either virus may also differ. M-MuLV encodes only viral structural genes, and its pathogenesis may involve the generation of recombinant mink cell focus-forming-like genomes (40) as well as activation of specific cellular genes (7, 8, 36 (23, 29) or to the v-abl gene product (46) have also been documented, and these also appear to be strain specific. A glycosylated form of the v-abl product has been found and may well be expressed on the cell surface (43) . Although it is clear that this glycosylated product is not necessary for transformation or tumor induction, such a product could serve as an immunological target.
In regards to target cell tropism, a comparison of in vitro and in vivo responses may be of interest. Although A-MuLV does not directly transform thymocytes in vitro (30) , it rapidly induces thymic lymphomas. This process, which is almost as rapid as nonthymic lymphoma induction, depends on the molecular form of the v-abl gene, and the v-abl gene product is readily detected in the resulting tumors. Therefore, it seems likely that thymoma induction is mediated at least in part by v-abl. The phenotype of most of the A-MuLV thymomas we analyzed is apparently different from typical A-MuLV pre-B-or B-cell tumors and from M-MuLV T-cell tumors in that most cells express undetectable quantities of the lineage-restricted markers B220, Thy-1, Ly-1, and Lyt-2. In this connection, Cook found that many thymomas induced by A-MuLV (P120) with M-MuLV helper were Thy-1-(6); the proportion of such tumors is higher in our study than in hers, but that may reflect either the age of the mouse inoculated or the strain of A-MuLV or helper used. Experiments currently in progress with immunoglobulin and T-cell receptor probes will hopefully clarify the phenotype of these tumors. If 
